A New Cholesterol Pill Is Here: What Lipfendra's FDA Approval Means for Your Heart
Today is one of those days I’ve been waiting years for. This morning the FDA approved a medicine called Lipfendra, known by its scientific name enlicitide. It’s the first PCSK9 inhibitor you can take as a once-daily pill. If that sentence doesn’t mean much to you yet, stay with me, because this is great news, and by the end you’ll understand why I’m this excited. PCSK9 inhibitors are some of the most effective cholesterol-lowering medicines ever made, and until this morning the only way to get one was a shot. Now it comes in a tablet you swallow with your morning coffee.
The protein that works against your heart
Let me introduce you to PCSK9, because it sits at the center of this story.
Your liver is built to pull cholesterol out of your blood. It does this using tiny units on the surface of liver cells called LDL receptors. Picture them as garbage disposals. They grab LDL cholesterol out of your bloodstream and grind it away. The more of these disposals you have running, the lower your LDL stays, and LDL is the proven, direct driver of heart attacks, the number one cause of death in this country and around the world.
PCSK9 is a protein that works against that whole system. It clogs the garbage disposals. When PCSK9 binds to an LDL receptor, that disposal stops grinding and gets hauled off to be destroyed. Fewer working disposals means less cholesterol gets cleared from your blood, so your LDL climbs and stays high. In plain terms, PCSK9 behaves like a toxin against your arteries. It quietly jams the exact machinery your body uses to protect your heart.
We know this from human genetics, and the evidence is beautiful. A small number of people are born making very little active PCSK9. They run rock-bottom LDL levels their entire lives, and they almost never have heart attacks. Their arteries stay clean for decades. These are real people, tracked over generations, showing us what a low-PCSK9 life looks like. They get long lives and healthy hearts. The lower your PCSK9 activity runs, the better your body protects itself.
So the whole game in modern cholesterol care has been figuring out how to give everyone else that same protection. That’s what a PCSK9 inhibitor does.
What Lipfendra actually does
Lipfendra neutralizes PCSK9.
The drug is a specially engineered molecule that latches onto PCSK9 and holds it out of action, so it can no longer clog your garbage disposals. With PCSK9 out of the way, those disposals unclog and get back to running. They stay on the surface of your liver cells, they multiply, and they return to the work they were built for. Your liver starts grinding cholesterol out of your blood naturally, the way it did when you were younger and your arteries were clean. The drug simply lets your body get back to doing its own job.
The historic part is how you get all of that. It comes as a pill, one tablet you take once a day.
The numbers behind the approval
The FDA didn’t approve this on a hunch. Lipfendra was tested in a large clinical program called CORALreef, across thousands of adults with high LDL cholesterol, including people with an inherited form called familial hypercholesterolemia who battle very high LDL from a young age.
The results were terrific. At 24 weeks, Lipfendra lowered LDL cholesterol by 56 percent compared to placebo in the main study, and by 59 percent in the group with the inherited condition. For a patient sitting at an LDL of 160, a drop like that can bring the number down into a range we’d celebrate. These are the kinds of reductions we used to see only with injections.
Why a pill changes the conversation
The injectable PCSK9 inhibitors we’ve had, medicines like Repatha and Praluent, and the twice-yearly injection Leqvio, are wonderful drugs. I prescribe them and I’ve watched them bring patients’ numbers down. Some people, though, hesitate at the idea of a shot. They don’t like needles, or the injection schedule doesn’t fit their life, or the pharmacy logistics wear them down.
A once-daily pill erases that hurdle. Swallowing a tablet is the most familiar thing in the world for anyone who already takes a morning medication. For patients who wanted this level of cholesterol lowering but balked at an injection, Lipfendra opens the door. More people getting to a healthy LDL means more heart attacks prevented, and that’s the entire point of what I do.
Who I’m already thinking about
The moment I read the approval, a handful of my patients came to mind.
People whose LDL stays too high even on a statin plus ezetimibe, and who need one more strong push to reach goal. Patients who can’t tolerate statins because of muscle aches and have been looking for a powerful alternative. Families carrying inherited high cholesterol who’ve fought their numbers since their twenties. Anyone at high risk who wants the protection of a PCSK9 inhibitor in pill form. For all of them, this is an option that wasn’t on the table yesterday.
My take
I’ve spent my career telling patients that cholesterol is one of the most controllable risks we have for the heart. Every few years a tool comes along that makes that promise easier to keep, and this is one of the big ones. We now have a once-a-day pill that switches off a protein working against your arteries and hands your liver back its natural power to clear cholesterol. That’s a wonderful thing to be able to offer.
If your LDL has been stubborn, or you’ve wanted this kind of cholesterol lowering without an injection, bring Lipfendra up at your next visit. For a fuller patient guide, including dosing, how it compares to the other PCSK9 inhibitors, and side effects, see my full write-up on Lipfendra (enlicitide). I expect to be reaching for it soon, and I couldn’t be happier that it’s finally here.
This post is for education and isn’t a substitute for personal medical advice. Talk with your own physician about whether a PCSK9 inhibitor is right for you.